23:34 , Jul 25, 2019 |  BC Extra  |  Financial News

July 25 Financial Quick Takes: Livongo, Castle pop after IPOs; plus a K2HV-Evelo deal, earnings beats for AZ & Roche, and more

Livongo, Castle rise in first trading day  Livongo Health inc. (NASDAQ:LVGO) and Castle Biosciences Inc. (NASDAQ:CSTL) each posted gains in their first day of trading Thursday after pricing upsized IPOs. Digital health play Livongo added...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
20:52 , May 30, 2019 |  BC Extra  |  Clinical News

May 30 Clinical Quick Takes: Cancer report shows decline in mortality from melanoma; plus Cara, Novartis

Decrease in mortality from melanoma attributed to checkpoint inhibitors  The rate of death due to melanoma of the skin declined by 8.5% per year during 2014-16 among men and 6.3% per year in 2013-16 among...
23:21 , May 23, 2019 |  BC Extra  |  Company News

With Merck veterans at the helm, Nektar launches subsidiary for pain compound

Nektar has been signaling for months that it planned to create a subsidiary to house analgesic NKTR-181, with a financial partner on board to fuel a commercial launch. Now that it has launched Inheris, the...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
20:48 , Oct 23, 2018 |  BC Extra  |  Company News

Management tracks: Celgene, Seres, AC Immune

Celgene Corp. (NASDAQ:CELG) hired Alise Reicin as president of global clinical development, a newly created position. She was SVP and head of global clinical development in R&D at the EMD Serono business of Merck KGaA...
17:49 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Cara raises $85.5M follow-on

Cara Therapeutics Inc. (NASDAQ:CARA) raised $85.5 million on July 18 through the sale of 4.5 million shares at $19 in a follow-on underwritten by Jefferies, BofA Merrill Lynch, Piper Jaffray, Stifel, Canaccord Genuity, Needham, H.C....
14:53 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Cara's IV analgesic meets in Phase III for postoperative pain

Cara Therapeutics Inc. (NASDAQ:CARA) said IV CR845 met the primary and secondary endpoints in the adaptive Phase II/III CLIN3001 trial to treat postoperative pain in patients undergoing abdominal surgery. On the primary endpoint, the 1...
20:24 , Jun 27, 2018 |  BC Extra  |  Clinical News

Cara gains after analgesic readout

Cara Therapeutics Inc. (NASDAQ:CARA) added $1.62 (10%) to $18.06 Wednesday after IV CR845 met the primary and secondary endpoints in the adaptive Phase II/III CLIN3001 study to treat postoperative pain in patients undergoing abdominal surgery....